radical prostatectomy for clinically localized prostate cancer. J Urol 161:329, 1.999, American Urological Association Annual
Meeting, Dallas TX, May 1.999);(Zisman A, Pantuck A, deKernion JB, Tso C‐L, Belldegrun A: G250‐GM‐CSF: a novel RCC specific
tumor vaccine. American Urological Association Annual Meeting, Atlanta GA, April 2.000);(Zisman A, Pantuck A, deKernion J, Tso C‐
L, Belldegrun A: G250‐GM‐GSF: A novel fusion protein serving as a specific tumor vaccine for renal cell carcinoma. Western Section
American Urological Association Annual Meeting, Palm Desert CA, 2.000);(Wu L, Carey M, Matherly J, Belldegrun AS, deKernion J:
Creating chimeric transcriptional regulatory elements that greatly augment the activity and specificity over the natural prostate
specific PSA enhancer. American Association for Cancer Research Annual meeting, San Francisco CA, April, 2.000);(Pantuck AJ,
Zisman A, Shvarts O, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS: Natural history and the role of nephrectomy in the biology of
RCC: the UCLA experience. Proceedings of ASCO 19:343a, 2.000, American Society of Clinical Oncology Annual Meeting, New
Orleans, LA, May 2.000);(Pantuck AJ, Zisman A, Chao D, Dorey F, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS: Regional
lymphadenopathy during cytoreductive nephrectomy predicts IL‐2 failure in patients with metastatic renal cell carcinoma. American
Society of clinical Oncology Annual Meeeting, 2.001);(Zisman A, Pantuck AJ, Chao D, Dorey F, Said JW, Gitlitz BJ, deKernion JB, Figlin
RA, Belldegrun AS: Should tumor size cut‐off point between RCC Stages T11997 and T21997 be lowered? J Urol 165(5)
Supplement:158, 2.001. American Urological Association Annual Meeting, Anaheim CA, June 2.001);(Zisman A, Pantuck AJ, Chao D,
Dorey F, Shvartz O, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS: Improved prognostication using a novel integrated staging
system (UISS) for renal cell carcinoma. J Urol 165(5) Supplement:161, 2.001. American Urological Association Annual Meeting,
Anaheim CA, June 2.001);(Belldegrun AS, Pantuck AJ, Zisman A, Shvarts O, Gitlitz BJ, deKernion JB, Figlin RA: Cytoreductive
nephrectomy and adjuvant immunotherapy significantly prolong life of patients with metastatic renal cell carcinoma (RCC). J Urol
165(5) Supplement:184, 2.001. American Urological Association Annual Meeting, Anaheim CA, June 2.001);(Graefen M, Karakiewicz
PI, Kattan, deKernion JB, et al: Cross‐cultural assessment of predictors of disease recurrence after radical prostatectomy: a pooled
analysis of 9256 cases. J Urol 165(5) Supplement:353, 2.001. American Urological Association Annual Meeting, Anaheim CA, June
2.001);(Zisman A, Pantuck AJ, Wieder J, Chao D, Dorey F, Said J, deKernion JB, Figlin RA, Belldegrun A: Risk group assessment and
clinical outcome to predict the natural history of patients with surgically resected renal cell carcinoma. American Society of Clinical
Oncology Annual Meeting, Orlando FL, 2.002);(Pantuck A, Zisman A, Chao D, Dorey F, deKernion J, Figlin R, Belldegrun A: A
comparison of Interferon versus Interleukin‐2 following nephrectomy for metastatic renal cell carcinoma. American Society of
Clinical Oncology Annual Meeting, Orlando FL, 2.002);(Pantuck AJ, Zisman A, Chao D, Dorey F, Flanigan R, deKernion JB, Figlin RA,
Belldegrun AS: Survival advantage of Interleukin‐2 over interferon immunotherapy when combined with cytoreductive
nephrectomy based on SWOG 8949‐matched populations. J Urol 167(4) Supplement: 166, 2.002. American Urological Association
Annual Meeting, Orlando FL, May 2.002);(Zisman A, Pantuck AJ, Chao D, Dorey F, Said JW, Figlin RA, deKernion JB, Belldegrun AS:
Renal cell carcinoma with IVC extension: the role of nephrectomy, immunotherapy and the relevance of the 1.997 TNM staging
system. J Urol 167(4) Supplement: 169, 2.002.American Urological Association Annual Meeting, Orlando FL, May 2.002);(Zisman A,
Pantuck AJ, Chao D, Dorey F, Said JW, deKernion JB, Figlin RA, Belldegrun AS: UISS‐based clinical algorithm to predict outcome of
patients with localized and advanced renal cell carcinoma. J Urol 167(4) Supplement: 169, 2.002. American Urological Association
Annual Meeting, Orlando FL, May 2.002),(Chen AA, Meng F, Taira RK, Kangarloo H, Churchill BM, deKernion JB Seamless,
simultaneous electronic clinical database entry and clinical note generation for prostate cancer: A glimpse into the future of
retrospective clinical research and medical documentation. American Urological Association Annual Meeting, San Antonio, TX, May
2.005)
Jean B. deKernion
D.M Quinlan, R.J Nelson y Patrick C. Walsh del Johns Hopkins Hospital
realizan el primer trabajo de investigación acerca de la restauracion de la funcion erectil por un injerto
de nervio sural en animales de experimentación (Quinlan D.M, Nelson R.J, Walsh P.C. Cavernous nerve
grafts restore erectile function in denervated rats. J Urol. 1.991;145:380383)
314
